Willow vs Regenics: Oral GLP-1 with Tracking vs Compounded Options
Quick verdict: Willow vs Regenics favors Willow for structured follow-up and progress tracking, while Regenics is the lower-cost entry point offering compounded semaglutide and tirzepatide from $139 first month under nurse-practitioner oversight.
Explore Willow’s telehealth program
Direct comparison: care model and core offering
Willow positions itself as a telehealth-first weight management program centered on an oral GLP-1 with progress tracking and follow-up consultations delivered by a licensed telehealth team. Regenics offers compounded semaglutide and tirzepatide prepared by U.S. licensed compounding pharmacies, with care overseen by licensed nurse practitioners and a Sermorelin peptide add-on option.
Five key differences between Willow and Regenics
1. Pricing and promotional structure
Regenics advertises compounded semaglutide at $139 first month and tirzepatide at $189 first month, with noted renewal increases to $199 and $279 respectively. Willow lists a starting price of 299. Promotional pricing and renewal terms are explicitly called out for Regenics; Willow’s captured page recorded a starting price of 299 and did not capture shipping or renewal detail.
2. Medication type and pharmacy model
Regenics supplies compounded medications, including semaglutide and tirzepatide, compounded by U.S. licensed pharmacies and shipped to patients. Willow offers an oral GLP-1 program; the source emphasizes program structure rather than a specific compounded product inventory. Both providers note that compounded medications, when offered, are not FDA-approved finished products and are not reviewed by FDA for safety, effectiveness or quality.
3. Clinical oversight and care delivery
Willow uses a licensed telehealth team and emphasizes follow-up consultations and behavioral support. Regenics is described as nurse-practitioner-led with licensed nurse practitioners reviewing intake and overseeing prescriptions. Regenics also highlights a LegitScript certified pharmacy network.
4. Support, tracking, and program focus
Willow frames its service as a structured weight management journey with progress tracking tools and follow-up support intended to convert medication efficacy into longer term outcomes. Regenics frames its service as a straightforward cash-pay entry to GLP-1 therapy and adds Sermorelin peptide therapy as a secondary option for recovery, energy, and muscle support.
5. Noted limitations and captured page issues
Regenics discloses that its promotional pricing applies to the first month only and that compounded medications are not FDA-approved finished products. Willow’s captured landing evidence included an error page and limited capture of shipping, fees, membership, or cancellation details; the source noted “No readable evidence captured” for some landing content.
Comparison table
| Criteria | Willow | Regenics |
|---|---|---|
| Primary offering | Oral GLP-1 program with progress tracking | Compounded semaglutide and tirzepatide; Sermorelin add-on |
| Starting price | Starting at 299 | Semaglutide $139 first month; tirzepatide $189 first month |
| Clinician oversight | Licensed telehealth team | Licensed nurse practitioners review intake and prescriptions |
| Support features | Progress tracking tools and follow-up consultations | Telehealth care plus peptide therapy option |
| Pharmacy and regulatory notes | Compounded medications, when offered, are not FDA-approved | Compounded by U.S. licensed pharmacies; not FDA-approved finished products |
How each provider frames suitability
Willow is described as best for users who want structured digital follow-up and behavioral scaffolding alongside medication. Regenics is described as best for patients seeking a straightforward cash-pay entry to GLP-1 therapy with lower initial pricing and a secondary peptide option.
See Willow’s progress tracking approach
Regulatory and safety qualifiers to note
Both sources emphasize that treatment is available only when a licensed clinician determines it is medically appropriate. Both note that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality. Regenics additionally notes its pharmacy network is LegitScript certified. Where the captured landing page was incomplete or returned errors, that limitation is reported in the source capture.
View Regenics pricing and options
Conclusion: Willow vs Regenics
In comparing Willow vs Regenics, choose Willow if you prioritize a telehealth-first program that pairs an oral GLP-1 with progress tracking tools and follow-up consultations delivered by a licensed telehealth team. Choose Regenics if you need a lower-cost cash-pay entry to compounded semaglutide or tirzepatide from $139 first month, nurse-practitioner oversight, and the option of Sermorelin peptide therapy. Both require licensed clinician review and both note that compounded medications are not FDA-approved finished products.